Antibiotics have served as the mainstay of ... treated during the open-labeled phase with a 10-day course of 0.75% metronidazole gel and in which asymptomatic responders were then randomized ...
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
In general, strive to use antibiotics covering a spectrum no ... If oral therapy is possible: Nonsevere: metronidazole 500 mg three-times daily (t.i.d.) orally for 10 days; Severe: vancomycin ...
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
GlobalData on MSN9d
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.
AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...
11d
AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...
AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback